Close Menu

stock offering

The firm is considering selling off its genetic testing and biomarker development business, including its CLIA lab.

Exact Sciences will use the funds to support clinical trials of its stool-based DNA colorectal cancer screening test.

Uses of the proceeds include funding clinical trials and obtaining FDA clearance for its sDNA colorectal cancer screening test.

The registration allows Exact Sciences to sell up to $150 million in securities, though it said that it has no immediate plans to do so.

Sequenom will not receive any of the proceeds of the sale of these shares by the selling stockholders, who purchased their shares through a private placement in May.

The money will help Wafergen commercially launch its high-throughput PCR system "imminently," according to a company official; and bolster the company's dwindling cash reserves in the interim.

The firm said that it will use funds from the offering to support commercialization of its SmartChip Real-Time PCR System including scale up of manufacturing capabilities for its instruments and chips.

Genomic Health has filed a replacement shelf registration for up to 10 million shares of its common stock in one or more offering.

The firm will use the proceeds to develop and commercialize its lead drug for depression, fund clinical trials for it coronary vasodilator, and other things.

The firm's full-year revenues were up 26 percent, according to the preliminary results. It also expects to offer all remaining shares of common stock on its existing shelf registration statement.

Pages

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.